Cargando…
Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
Autores principales: | Erçalışkan, Abdülkadir, Avcı, Fatma Zehra, Eşkazan, Ahmet Emre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727713/ https://www.ncbi.nlm.nih.gov/pubmed/36373683 http://dx.doi.org/10.4274/tjh.galenos.2022.2022.0397 |
Ejemplares similares
-
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013) -
Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019) -
First Report of Severe Autoimmune Hemolytic Anemia During Eltrombopag Therapy in Waldenström Macroglobulinemia-Associated Thrombocytopenia
por: Shen, Yingying, et al.
Publicado: (2021) -
Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
por: Aiello, Andrea, et al.
Publicado: (2017)